Matthew Phipps

Stock Analyst at William Blair

(0.40)
# 4,121
Out of 4,948 analysts
3
Total ratings
n/a
Success rate
-6.7%
Average return

Stocks Rated by Matthew Phipps

NuCana
Aug 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.73
Upside: -
Amgen
May 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $296.47
Upside: -
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $25.07
Upside: -